|
" Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial "
\ Ali Sonbolestan
; Heshmatollah Ghanbari, Farzan Kianersi
| center
|
:
|
Isfahan University of Medical Sciences
|
| Document Type
|
:
|
Latin Dissertation
|
| Language of Document
|
:
|
English
|
| Record Number
|
:
|
107844
|
| Doc. No
|
:
|
T17155
|
| Call number
|
:
|
WK835,S698i,2016
|
| Main Entry
|
:
|
Sonbolestan, Ali
|
| Title & Author
|
:
|
Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial\ Ali Sonbolestan
|
| College
|
:
|
Schools, Medical
|
| Date
|
:
|
, 2016
|
| Degree
|
:
|
Speciality
|
| field of study
|
:
|
Ophtalmology
|
| Page No
|
:
|
{No paging}: diag, tab
|
| Note
|
:
|
This is a research dissertation with project ID: 394740
|
|
|
:
|
علی سنبلستان
|
| Abstract
|
:
|
Abstract The aim of this study is to evaluate theshort-term effects of a single intravitreal injection of1.25 mg Bevacizumab combined with 300 lg/0.1 mLDiclofenac (IVB/D) versus 1.25 mg intravitreal Bevacizumab(IVB) alone in the treatment of naive diabeticmacular edema (DME). In this prospective, randomizedclinical trial, 80 eyes were included in the final analysis;42 and 38 of which in the IVB and IVB/D groups,respectively. The primary outcome measure was achange in best-corrected visual acuity (BCVA) inlogMAR at week 4. The secondary outcomes includedchanges in central macular thickness (CMT), macularvolume, and potential injection-related complications.Significant improvement ofBCVAwas demonstrated inboth study arms (mean reductions in LogMAR:-0.088 ± 0.278,-0.228 ± 0.330 for IVB and IVB/D,respectively). The difference in BCVA changes was infavor of IVB/D; however, not to a statistically significantlevel (P = 0.160). Significant reduction of CMTwas documented in both study arms (mean reductions:82.43 ± 160.09 and 153.26 ± 163.85 for IVB andIVB ? IVD, respectively). Comparison of CMTchanges between groups showed that IVB/D reducedCMT more than that of IVB (P = 0.04). Effects onmacular volume corresponded to those of CMT. Noinjection-related complications or significant alterationsin intraocular pressure were observed in any of the studyarms. In treatment-naive DME, superiority of IVB/Dcombination therapy over IVB monotherapy may exist;especially as regards anatomical features. In our therapeuticarsenal for DME, IVD can be added as anadjunct to Bevacizumab.
|
| Descriptor
|
:
|
Macular Edema
|
|
|
:
|
Diabetic Retinopathy
|
|
|
:
|
Diclofenac
|
|
|
:
|
Bevacizumab
|
|
|
:
|
Intravitreal Injections
|
| Added Entry
|
:
|
Ghanbari, Heshmatollah, Thesis advisor
|
|
|
:
|
Kianersi, Farzan, Thesis advisor
|
| Translated Title Supplied by Cataloguer
|
:
|
مقایسه تاثیر تزریق داخل ویتره دیکلوفناک و آواستین در جهش مولکولی دیابت
|
| |